Molly Morton

Medicine · Health Sciences

12h-index343citations64works0.62yr avg
OpenAlex↗ORCID↗Google Scholar↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Ovarian cancer diagnosis and treatment(19), Intraperitoneal and Appendiceal Malignancies(14), Endometrial and Cervical Cancer Treatments(12), Cancer Immunotherapy and Biomarkers(8), Social Media in Health Education(7)

Publications64 total

Assessment of complete responses to immune checkpoint inhibitors by mismatch repair subtype in endometrial cancer
Gynecologic Oncology·2026
Real-world outcomes of immune checkpoint inhibitors in advanced and recurrent vulvar and vaginal cancer
Gynecologic Oncology·2026
Frailty and body composition as predictors of postoperative outcomes in patients with epithelial ovarian cancer undergoing neoadjuvant chemotherapy
Gynecologic Oncology·2025
Assessment of probiotic and prebiotic use in gynecologic cancer patients: a systematic review
American Journal of Obstetrics and Gynecology·2025
Cross-language insights: Comparing Spanish and English-language cervical cancer content on TikTok
Gynecologic Oncology·2025
Digital inequities and ovarian cancer treatment and survival
Gynecologic Oncology·2025
Associations between area-level digital inequities and cervical cancer treatment and outcomes
Gynecologic Oncology·2025
Evaluation of immunotherapy response in the radiated field in patients with recurrent endometrial and cervical cancer
Gynecologic Oncology·2025
The price of delay: Insurance-related treatment delays in patients with gynecologic cancer receiving immunotherapy
Gynecologic Oncology·2025
Scrolling surgeons: Assessment of social media and artificial intelligence usage in gynecologic oncology fellows and fellowship programs
Gynecologic Oncology Reports·2025Open Access
Exploratory evaluation of immunotherapy response and medication use in endometrial and cervical carcinoma
Gynecologic Oncology Reports·2025Open Access
Circulating extracellular vesicles protein expression for early prediction of platinum-resistance in high-grade serous ovarian cancer
Oncogene·2025· 4 citedOpen Access
Cross-language insights: Comparing Spanish and English-language cervical cancer content on TikTok
Gynecologic Oncology·2025· 1 cited
Management of Recurrent Endometrial Cancer Once Lifetime Cumulative Dose of Doxorubicin Has Been Reached: Is There a Role for Switching to Pegylated Liposomal Doxorubicin?
SSRN Electronic Journal·2025Open Access
Time toxicity associated with immunotherapy-related adverse events in cervical and endometrial cancer patients
Gynecologic Oncology·2024
Oncologic outcomes and adverse events with immunotherapy treatment among frail patients with gynecologic cancers
Gynecologic Oncology·2024
Assessment of endocrine toxicities among gynecologic oncology patients receiving immunotherapy
Gynecologic Oncology·2024
Immunotherapy: Is it all about timing?
Gynecologic Oncology·2024· 2 cited
Caring beyond the cost: Finance-related treatment delays in gynecologic cancer patients receiving treatment with immunotherapy
Gynecologic Oncology·2024
Venous and arterial thromboembolic events in gynecologic cancer patients receiving treatment with immunotherapy
Gynecologic Oncology·2024
page 1 of 4Next →

Frequent Co-authors

Laura Chambers(37), Julia Chalif(20), David M. O’Malley(19), Meng Yao(18), Floor Backes(15), Christa Nagel(14), Chad M. Michener(13), Robert Debernardo(13), David E. Cohn(12), Kristin Bixel(11), Casey Cosgrove(11), Max Horowitz(10), Roberto Vargas(10), Jessica Fulton(10), Anna Gonzalez(10), Anthony B. Costales(9), Anna Chichura(9), Morgan Gruner(9), Peter G. Rose(8), Paulina Haight(8)